Drugs in Dev. Oncology
Phase IV
JELMYTO Reports 68% Recurrence-Free Survival Rate at 3 Years in LG-UTUC Patients
Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing 4 mg mitomycin per mL gel indicated for primary chemoablative treatment of LG-UTUC in adults.
Product Name : Jelmyto
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 22, 2025
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Salix Announces Phase 2 Study of RELISTOR® in Resectable HNSCC
Details : Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.
Product Name : Relistor
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 03, 2024
Lead Product(s) : Naltrexone Methobromide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JELMYTO® Real-World Study Matches OLYMPUS in Cancer Response Rates
Details : Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel indicated for primary chemoablative treatment of LG-UTUC in adults.
Product Name : Jelmyto
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 05, 2024
Phase 4 Study Evaluates ADSTILADRIN® Use in Real-World Setting
Details : Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy delivering a human IFNα2b gene to the bladder for treating BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : Adstiladrin
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 24, 2024
Details : Lutathera (lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is an Advanced Accelerator Applications RLT approved in the United States for the treatment of SSTR-positive GEP-NETs.
Product Name : Lutathera
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
September 25, 2023
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
Details : Legend Biotech entered into the agreement with Janssen to develop, manufacture and commercialize cilta-cel for the treatment of multiple myeloma. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.
Product Name : Carvykti
Product Type : Cell and Gene therapy
Upfront Cash : $350.0 million
November 02, 2022
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NUBEQA significantly reduced the risk of death by 31%, offering men with non-metastatic castration-resistant prostate cancer (nmCRPC) extended survival for a greater chance of living longer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
August 01, 2021
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bristol Myers Squibb Statement on Opdivo (Nivolumab) Small Cell Lung Cancer U.S. Indication
Details : The trial demonstrated encouraging response rates and duration of response with Opdivo in SCLC, an aggressive and difficult-to-treat cancer.
Product Name : Opdivo
Product Type : Antibody
Upfront Cash : Inapplicable
December 29, 2020
Lead Product(s) : Ixazomib Citrate,Dexamethasone,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.
Product Name : Ninlaro
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2020
Lead Product(s) : Ixazomib Citrate,Dexamethasone,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CIBMTR Completes Enrollment in Yescarta® Long-Term Post-Marketing Safety Study
Details : Yescarta is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Product Name : Yescarta
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
